Literature DB >> 9888496

Epilepsy classification and factors associated with control in Saudi adult patients.

M Abduljabbar1, A Ogunniyi, A K Daif, A Al-Tahan, M Al-Bunyan, S Al-Rajeh.   

Abstract

There is insufficient information on the epilepsies in Saudi Arabia. The objectives were to classify the patients according to seizure types and epilepsies as well as to determine the factors associated with control. In a hospital-based study, clinical information, electroencephalographic and neuroimaging findings were utilized to classify the cases into seizure types and epilepsies according to ILAE criteria and to determine the factors statistically associated with control. In the study there were 826 patients (454 males and 372 females; mean age = 28.7 years; >80% below 30 years at onset). The seizure types were: generalized tonic-clonic (43.8%), partial seizure secondarily generalized (41.9%), myoclonic (8.4%), simple partial (1.3%), complex partial (1.3%) and absence (0.4%). About 15% of the classifiable epilepsies were symptomatic. Most symptomatic epilepsies occurred in people over the age of 50 years. One-year remission rate was 80% and the factors associated with control were: compliance, monotherapy, therapeutic drug level and seizure type. The results showed that epilepsy predominantly affected young adults and confirmed the association of partial epilepsy with clinical and CT abnormalities. The 1-year remission rate was comparable with reports from other studies as well as the factors associated with control in our patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9888496     DOI: 10.1016/s1059-1311(98)80010-1

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  2 in total

1.  Newly diagnosed seizures in adolescents: a comparative study.

Authors:  Hassan M Ismail
Journal:  J Family Community Med       Date:  2003-05

2.  Value of neuroimaging in epilepsy: An experience from Pakistan.

Authors:  Ahmed Bakhsh
Journal:  J Neurosci Rural Pract       Date:  2013-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.